How Treg cells impact CAR-T therapy: insights from the Cancer Correlative Science Unit
Diving into the intricate world of CAR-T cell therapy, Bita Sahaf shares insights from her work at the Cancer Correlative Science Unit in the Stanford Center for Cancer Cell Therapy (CA, USA). In this interview, Dr Sahaf discusses the practical aspects of biomarker discovery, patient-specific variability and potential strategies to enhance CAR-T efficacy by addressing Treg-mediated suppression.
Interview questions
- Tell us a bit about the purpose of the Cancer Correlative Science Unit and how it contributes to the advancement of CAR-T therapies.
- What role do Treg cells play in CAR-T therapy?
- In the context of CAR-T cell therapy, how do Treg cells affect efficacy post-treatment?
- What kind of biomarkers and/or immune checkpoint markers are associated with CD25+ FoxP3+ Treg cell-mediated immune suppression post CAR-T therapy?
- What kind of analytical methods do you employ to study these biomarkers?
- Are there specific types of cancer or circumstances where the interaction between CAR-T cells and Treg cells is particularly pronounced?
- How does patient-specific variability play into this and what are the implications for personalized treatment approaches?
- Are there any strategies to mitigate the Treg-mediated suppression of CAR-T therapies?
